Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.72|
|52 Week High||AU$0.51|
|52 Week Low||AU$1.08|
|1 Month Change||5.11%|
|3 Month Change||21.01%|
|1 Year Change||-25.00%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-33.02%|
Recent News & Updates
We're Interested To See How Invex Therapeutics (ASX:IXC) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|IXC||AU Pharmaceuticals||AU Market|
Return vs Industry: IXC underperformed the Australian Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: IXC underperformed the Australian Market which returned 20.3% over the past year.
Stable Share Price: IXC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: IXC's weekly volatility (7%) has been stable over the past year.
About the Company
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.
Invex Therapeutics Fundamentals Summary
|IXC fundamental statistics|
Is IXC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IXC income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.03|
|Net Profit Margin||0.00%|
How did IXC perform over the long term?See historical performance and comparison
Is Invex Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IXC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IXC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IXC is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: IXC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IXC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IXC is good value based on its PB Ratio (1.7x) compared to the AU Pharmaceuticals industry average (3.5x).
How is Invex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invex Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Invex Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: IXC is currently unprofitable.
Growing Profit Margin: IXC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IXC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IXC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IXC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: IXC has a negative Return on Equity (-7.12%), as it is currently unprofitable.
How is Invex Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: IXC's short term assets (A$32.7M) exceed its short term liabilities (A$658.6K).
Long Term Liabilities: IXC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IXC is debt free.
Reducing Debt: IXC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IXC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IXC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 35% each year
What is Invex Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IXC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IXC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IXC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Invex Therapeutics has no CEO, or we have no data on them.
Experienced Board: IXC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Invex Therapeutics Ltd's employee growth, exchange listings and data sources
- Name: Invex Therapeutics Ltd
- Ticker: IXC
- Exchange: ASX
- Founded: 2019
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$53.359m
- Shares outstanding: 75.15m
- Website: https://www.invextherapeutics.com
- Invex Therapeutics Ltd
- 38 Rowland Street
- Level 1
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 07:03|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.